It has been suggested that few institutions have all the essential elements necessary to train clinical investigators in oncology. These essential elements are well developed at the University of Texas Health Science Center at San Antonio (UTHSCSA): we have a long track record of training academic oncologists; we have a broad and well-supported research effort organized into an NCI-designated Cancer Center, we have a faculty actively pursuing translational research programs; we have a well-established local and national clinical investigations program; and we have an ongoing, structured program of didactic training. These factors make the UTHSCSA an ideal institutional environment for the training of clinical investigators. Our program will identify physician candidate trainees from medical, surgical, and radiation oncology. The resources of our NCI-designated Cancer Center, the Institute for Cancer Research and Care (ICRC), will be utilized in the program. For Phase I of their training, trainees will select an ICRC member as a mentor for their training in laboratory research skills. The completion of the training period will be marked by the submission of a detailed clinical investigation proposal. At this point, trainees will return to their clinical divisions to perform this research using the skills they have mastered. An Advisory Committee composed of scientists and clinicians from all the relevant disciplines will oversee the program and progress of each trainee. Thus, the key elements required to develop the clinical investigator trained in basic science techniques are in place at the UTHSCSA. Our proposal is designed to provide a structure and mechanism of support to continue and expand our program of training the oncology physician scientist.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Physician Scientist Award (Program) (PSA) (K12)
Project #
5K12CA001723-04
Application #
2084365
Study Section
Special Emphasis Panel (SRC (72))
Project Start
1992-09-05
Project End
1997-08-31
Budget Start
1995-09-01
Budget End
1996-08-31
Support Year
4
Fiscal Year
1995
Total Cost
Indirect Cost
Name
University of Texas Health Science Center San Antonio
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
800772162
City
San Antonio
State
TX
Country
United States
Zip Code
78229
Kazhdan, I; Long, L; Montellano, R et al. (2006) Targeted gene therapy for breast cancer with truncated Bid. Cancer Gene Ther 13:141-9
Kazhdan, Irene; Marciniak, Robert A (2004) Death receptor 4 (DR4) efficiently kills breast cancer cells irrespective of their sensitivity to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). Cancer Gene Ther 11:691-8
Wang, W; Waters, S J; MacDonald, J R et al. (2001) Irofulven (6-hydroxymethylacylfulvene, MGI 114) induces caspase 8 and 9-mediated apoptosis in human pancreatic adenocarcinoma cells. Anticancer Res 21:1789-94
Raymond, E; Sun, D; Izbicka, E et al. (1999) A human breast cancer model for the study of telomerase inhibitors based on a new biotinylated-primer extension assay. Br J Cancer 80:1332-41
Yang, L M; Tin-U, C; Wu, K et al. (1999) Role of retinoid receptors in the prevention and treatment of breast cancer. J Mammary Gland Biol Neoplasia 4:377-88
Sharma, S; Raymond, E; Soda, H et al. (1998) Dimethyl sulfoxide (DMSO) causes a reversible inhibition of telomerase activity in a Burkitt lymphoma cell line. Leuk Res 22:663-70
Sharma, J J; Razvillas, B; Stephens, C D et al. (1997) Phase II study of flutamide as second line chemotherapy in patients with advanced pancreatic cancer. Invest New Drugs 15:361-4
Sharma, S; Raymond, E; Soda, H et al. (1997) Preclinical and clinical strategies for development of telomerase and telomere inhibitors. Ann Oncol 8:1063-74
Alsina, M; Boyce, B; Devlin, R D et al. (1996) Development of an in vivo model of human multiple myeloma bone disease. Blood 87:1495-501
Alsina, M; Boyce, B F; Mundy, G R et al. (1995) An in vivo model of human multiple myeloma bone disease. Stem Cells 13 Suppl 2:48-50

Showing the most recent 10 out of 11 publications